Antibody-Decorated Lipid Nanoparticles Face Formidable Translation Hurdles Beyond the Liver

Lipid nanoparticles have emerged as standard non-viral transport platforms for nucleic acid therapeutics following the widespread deployment of messenger RNA vaccines, yet achieving precise delivery outside the liver remains a persistent scientific obstacle. In a mini-review published in AAPS Open, researchers Janell Ko, Jordan Tom, and Miffy H. Y. Cheng systematically evaluated the structural, physiological, and bioconjugation principles governing antibody-mediated active targeting for lipid nanoparticle systems. While clinical formulations have achieved regulatory success for genetic disorders and viral vaccination, unmodified nanoparticles rapidly clear from the bloodstream and concentrate heavily within hepatic tissues following systemic administration. Engineering targeting antibodies onto the exterior surface of lipid nanoparticles is widely investigated to circumvent this non-specific biodistribution by promoting receptor-mediated uptake into specified cell types. However, decades after early immunoliposome investigations first explored antibody functionalization on lipid bilayers, no active-targeting nanomedicines have achieved regulatory approval for human clinical therapy. The authors surveyed preclinical achievements alongside persistent translational bottlenecks, examining why laboratory targeting efficacy frequently fails to reproduce in human trials.

Clinical milestones have proven that systemically administered nucleic acid formulations can treat severe diseases when the therapeutic objective aligns with natural biodistribution patterns. The United States Food and Drug Administration approved Onpattro in 2018 for hereditary transthyretin-mediated amyloidosis, establishing small interfering RNA delivery via lipid carriers, followed by the deployment of Spikevax, Comirnaty, and mResvia for respiratory and pandemic pathogens. Upon entering the circulation, lipid nanoparticles experience rapid shedding of diffusible short-chain polyethylene glycol lipids, such as PEG-dimyristoyl glycerol with fourteen-carbon chains, exposing the hydrophobic core to circulating plasma proteins. The resulting biological coating, termed the protein corona, becomes predominantly enriched with apolipoprotein E. Because apolipoprotein E possesses natural affinity for low-density lipoprotein receptors expressed abundantly on hepatocytes, standard formulations are rapidly absorbed into liver tissue with a bloodstream half-life of roughly thirty minutes, creating severe dose-limiting hepatotoxicity and leaving extrahepatic disease sites unaddressed.

To alter this predetermined biodistribution, researchers explore passive and active engineering strategies to redirect carrier trajectories through the body. Passive methods manipulate structural parameters such as surface charge, size, morphology, and lipid helper composition to tune protein adsorption, exemplified by selective organ targeting platforms that incorporate a fifth charged lipid to divert payloads toward the lungs or spleen. Active targeting instead grafts specific biological recognition ligands, including aptamers, peptides, and full-length monoclonal antibodies or engineered antibody fragments, onto the nanoparticle exterior. Monoclonal antibodies serve as the preferred targeting ligand owing to their established clinical manufacturing record, elevated receptor binding affinities, and exquisite target specificity. In theory, displaying antibodies against unique cellular markers allows circulating nanoparticles to dock directly onto intended cell surface receptors and induce internalization through receptor-mediated endocytosis, theoretically shielding healthy tissues from off-target genetic modification or toxic payload accumulation.

The physical route that targeted nanoparticles must navigate across vascular boundaries presents distinct physiological hurdles depending on the biological location of the intended tissue. To reach extravascular parenchymal cells in solid organs, systemically administered lipid nanoparticles must first exit the bloodstream through extravasation, passing across the endothelial lining of microvessels before migrating through dense extracellular matrix networks. Grafting typical immunoglobulin G molecules, which measure roughly ten to fifteen nanometers in diameter, increases the total hydrodynamic diameter of a fifty-to-one-hundred-nanometer nanoparticle by an estimated twenty to thirty nanometers. Once reaching the destination cell, nanoparticles must enter through clathrin-dependent, caveolin-dependent, or pinocytic uptake and achieve endosomal escape into the cytosol before lysosomal degradation neutralizes the nucleic acid cargo.

Recognizing the formidable extracellular barriers protecting solid organs, recent engineering efforts have shifted from targeting solid disease tissues toward targeting circulating immune cells directly within the vascular lumen. Circulating lymphocytes, monocytes, neutrophils, and macrophages are continuously accessible within the bloodstream, completely eliminating the physiological necessity for extravasation and extracellular matrix permeation. Furthermore, immune cells exhibit well-defined, lineage-restricted cell surface antigens, such as CD3 on T cells or CD19 on B cells, offering precise molecular handles to restrict nanoparticle internalization to distinct cell subsets. Immune cells also possess versatile intrinsic internalization machinery, including continuous pinocytosis and phagocytic engulfment. However, delivering genetic material into immune cells introduces distinct intracellular difficulties: circulating leukocytes maintain lower baseline metabolic rates, express active pattern-recognition sensors that intercept and destroy foreign nucleic acids, and initiate potent inflammatory signaling cascades that can induce premature cytokine toxicity or silence cargo translation.

A critical biological complication highlighted in the review involves the unintended recognition of antibody-functionalized carriers by immune receptors found across non-target populations. Nearly every circulating human immune lineage and platelet population expresses surface Fc gamma receptors, with T lymphocytes representing the only notable exception. These receptors naturally recognize the crystallizable fragment domain of full-length immunoglobulins to trigger phagocytosis and immune clearance. When full-length antibodies are conjugated onto lipid nanoparticles without structural masking or orientation control, exposed Fc domains prompt non-specific uptake by circulating phagocytes, systematically diverting the therapeutic vector away from the desired receptor target and diminishing therapeutic gene expression.

Formulating antibody-conjugated lipid nanoparticles requires navigating severe bioconjugation trade-offs between ligand orientation, structural integrity, and synthetic reproducibility. One-pot assembly strategies mix targeting antibodies conjugated to lipid headgroups alongside ionizable lipids, cholesterol, and helper lipids during microfluidic self-assembly, simplifying workflow requirements by eliminating secondary purification. Nevertheless, experimental analyses indicate that more than fifty percent of conjugated ligands become trapped within the internal aqueous core of the nanoparticle during self-assembly, rendering them entirely inaccessible for cell-surface binding while risking destabilizing physical interactions with the encapsulated messenger RNA cargo. Consequently, post-insertion methods on preformed nanoparticles remain the preferred alternative, utilizing chemical cross-linkers like maleimide-thiol linkages or bioorthogonal click reactions. Yet post-insertion workflows require downstream purification steps to separate unreacted antibodies, which consistently diminishes product yield, promotes particle aggregation, and strains overall colloidal stability.

The chemical linkages that tether antibodies to lipid anchors also suffer from structural instability and off-target cross-reactivity under physiological conditions. The classical maleimide-thiol coupling reaction attaches sulfhydryl groups on reduced antibodies to maleimide-functionalized pegylated lipids. Because reducing agents such as dithiothreitol or tris(2-carboxyethyl)phosphine cleave disulfide bonds without regioselectivity, reacting the four interchain disulfide bonds of an immunoglobulin G molecule generates up to eight unpredictable conjugation sites, yielding random antibody orientations that conceal antigen-combining variable regions. In addition, unreacted maleimide handles can covalently cross-react with circulating thiol-containing serum proteins in vivo to trigger adverse complement activation, while formed thioether linkages undergo retro-Michael exchange reactions with blood thiols that displace targeting antibodies during circulation. To establish robust regioselectivity, researchers increasingly deploy strain-promoted azide-alkyne cycloaddition click reactions between lipid-anchored azides and dibenzocyclooctyne-modified antibodies, an approach that demonstrated a two-fold delivery enhancement to placental tissue in pregnant murine models.

To overcome the unpredictability of chemical cross-linking, bioengineering approaches have introduced modular adapter systems that capture native antibodies without denaturing reduction steps. The anchored secondary single-chain variable fragment enabling targeting platform, termed ASSET, embeds a membrane-anchored lipoprotein into the nanoparticle shell that selectively binds the Fc stem of antibodies, ensuring outward orientation of the targeting antigen-binding sites and extending survival from twenty-eight to forty-six days in a mantle cell lymphoma murine xenograft model. Similarly, the TP1107 anti-Fc nanobody displayed on lipid nanoparticles captures antibodies in optimal stereochemical configurations, producing an eight-fold increase in target binding. Another approach, termed GrAb, fuses apolipoproteins to antibody heavy chains, allowing spontaneous insertion into lipid envelopes while mimicking endogenous protein coronas to achieve a 2.7-fold increase in p53 messenger RNA expression within HER2-positive cancer models. Additionally, bispecific antibodies that concurrently bridge nanoparticle polyethylene glycol chains and cancer surface antigens have mediated tumor delivery during pre-targeting protocols.

Despite these technological innovations, fundamental biophysical parameters on the nanoparticle surface remain exceedingly difficult to characterize and control. Increasing the surface density of targeting antibodies initially enhances binding avidity toward target cells, yet excessive crowding generates steric hindrance that obstructs receptor access and recruits opsonizing blood proteins that accelerate macrophage-mediated elimination. Furthermore, targeting ligands can dissociate prematurely while navigating the bloodstream; recent liposomal investigations revealed that over fifty percent of lipid-anchored antibodies detached within four hours of systemic circulation. Traditional lipid nanoparticles incorporate short-chain polyethylene glycol lipids with short retention periods, which may limit detachment but simultaneously restricts particle circulation to roughly thirty minutes, providing insufficient time for nanoparticles to search out scarce extrahepatic receptors.

Historical precedents from four decades of immunoliposome oncology trials illustrate the severe translational disconnect between preclinical efficacy and human clinical performance. Translating these lessons to modern lipid nanoparticles, contemporary researchers are prioritizing in vivo immune engineering over solid tumor delivery. Preclinical anti-CD5 lipid nanoparticles successfully generated functional chimeric antigen receptor T cells in vivo to alleviate hypertensive cardiac injury in mice, and cell-targeted small interfering RNA platforms have demonstrated target knockdown in non-human primate T cells. Clinical evaluations are now initiating, including a phase I trial evaluating anti-CD8 lipid nanoparticles for targeted autoimmune therapies.

Subject of Research: Antibody-based active targeting strategies and translational challenges for lipid nanoparticle delivery systems

Article Title: Considerations on antibody-based active targeting strategies for lipid nanoparticle delivery systems

Article References: Ko, J., Tom, J., & Cheng, M. H. Y. (2026). Considerations on antibody-based active targeting strategies for lipid nanoparticle delivery systems. AAPS Open, 12(1), Article 19. https://doi.org/10.1186/s41120-026-00159-1

Image Credits: AI Generated

DOI: 10.1186/s41120-026-00159-1

Keywords: lipid nanoparticles, active targeting, nucleic acid delivery, monoclonal antibodies, hepatic accumulation, protein corona, apolipoprotein E, maleimide-thiol chemistry, strain-promoted azide-alkyne cycloaddition, Fc gamma receptors, immunoliposomes, extravasation, CAR-T cell engineering, endosomal escape, extrahepatic delivery, pegylated lipids, bioconjugation